Search Results
Apr 23, 2026, 08:30 ET Servier completes the acquisition of Day One Biopharmaceuticals
tovorafenib, which is being investigated in additional indications, Day One's pipeline includes Emi-Le (emiltatug ledadotin), a novel antibody drug conjugate (ADC) and DAY301, a targeted therapy in rare cancers. "Welcoming Day One to Servier marks an important next chapter in how we are expanding our presence
More news about: Servier
Apr 23, 2026, 04:14 ET Mabwell Initiates Phase III Clinical Study of its Nectin-4-Targeting ADC 9MW2821 for the Treatment of Triple-Negative Breast Cancer
announces the initiation of a Phase III clinical study of its proprietary Nectin-4-targeting ADC (R&D code: 9MW2821) for the treatment of triple-negative breast cancer (TNBC). 9MW2821 is the world's first Nectin-4 ADC to enter Phase III clinical study for TNBC. This marks the fourth pivotal trial initiated
More news about: Mabwell
Apr 23, 2026, 03:38 ET 邁威生物靶向Nectin-4 ADC創新藥 9MW2821 啟動治療三陰性乳腺癌的III期臨床研究
TOPi-ADC 已成為 TNBC 標准療法之後的主要治療手段。既往 TOPi-ADC 治療失敗的 TNBC 患者治療仍以化療為主，有較大未被滿足的臨床需求。9MW2821 是全球首個披露 TNBC 有效性數據的靶向 Nectin-4 ADC，曾獲 FDA 授予「快速通道認定」（FTD）用於治療局部晚期或轉移性 Nectin-4 陽性 TNBC。TNBC 是其繼尿路上皮癌（UC）、宮頸癌（CC）後，第 3 個進入 III 期臨床研究階段的腫瘤類型。目前，9MW2821 也已在美國針對 ADC 經治 TNBC
More news about: 邁威生物
Apr 23, 2026, 02:47 ET 2026 ASCO | Mabwell to Present Latest Clinical Data on 9MW2821 Combined with Toripalimab for Urothelial Carcinoma in Oral and Poster Presentations
innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that two latest clinical study results of its Nectin-4-targeting ADC 9MW2821 in combination with toripalimab for urothelial carcinoma will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
More news about: Mabwell
Apr 23, 2026, 02:05 ET 2026 ASCO | 邁威生物將以口頭報告和壁報形式公布 9MW2821 聯合特瑞普利單抗用於尿路上皮癌的最新臨床數據
2026年4月23日 /美通社/ -- 邁威生物（688062.SH），一家全產業鏈布局的創新型生物製藥公司，宣布將於當地時間 2026 年 5 月 29 日 - 6 月 2 日在美國芝加哥舉行的 2026 美國臨床腫瘤學會（ASCO）年會分別以口頭報告和壁報形式公布靶向 Nectin-4 ADC 創新藥 9MW2821 聯合特瑞普利單抗用於尿路上皮癌的兩項最新臨床研究結果。 口頭報告摘要標題： Bulumtatug fuvedotin (BFv; 9MW2821) plus toripalimab in patients with
More news about: 邁威生物
Apr 22, 2026, 07:00 ET Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting
osimertinib (a tyrosine kinase inhibitor) plus chemotherapy and outperforms the approved Trop-2 ADC Dato-DXd (DATROWAY®), the EGFR-cMET bispecific antibody amivantamab (RYBREVANT®) and the experimental EGFR-HER3 ADC izalontamab brengitecan, supporting potential use across first-, second-, and third-line treatment
More news about: Actinium Pharmaceuticals, Inc.
Apr 22, 2026, 05:40 ET Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth
indications were approved in China, which included an anti-PD-L1/TGF-βRII bi-functional fusion protein and an indication expansion for HER2-targeting ADC.In terms of pipeline advancement, the Company obtained 26 clinical trial approvals and had 8 new drug applications accepted in China across key
More news about: Hengrui Pharma
Apr 21, 2026, 22:00 ET Case Report of Mabwell's Nectin-4 targeting ADC (9MW2821) in Cervical Cancer Published in The New England Journal of Medicine
biopharmaceutical company with a fully integrated industrial chain, announced that a recent clinical case report on its self-developed novel Nectin-4 ADC (bulumtatug fuvedotin, R&D code: 9MW2821) for the treatment of cervical cancer has been published in The New England
More news about: Mabwell
Apr 21, 2026, 22:00 ET 邁威生物靶向Nectin-4 ADC（9MW2821）治療宮頸癌的病例報告登上《新英格蘭醫學雜誌》
fuvedotin，研發代號：9MW2821）治療宮頸癌的最新臨床病例報道近日登上國際頂尖醫學期刊《新英格蘭醫學雜誌》（NEJM，影響因子：78.5）。 該文章由宜賓市第二人民醫院腫瘤中心汪善兵主任團隊發表，首次向全球揭示了晚期宮頸癌患者在接受新型Nectin-4 ADC（9MW2821）治療後，出現的罕見肝臟「假性進展」現象。「假性進展（pseudoprogression）」一般指在免疫治療初期腫瘤原有病灶短期內增大或出現新病灶，不伴有疾病惡化，後期病灶表現為穩定或縮小的現象，通常並非真正的腫瘤進展。文章報告了一例晚期轉移性宮頸鱗狀細胞癌患者，此患者既往含鉑化療失敗，未接受過免疫治療。在接受9MW2821治療短短兩個週期後，患者基線轉移病灶顯著縮小，血清鱗狀細胞癌抗原（SCC）更是發生「斷崖式」下降——從37.0
More news about: 邁威生物
Apr 21, 2026, 20:53 ET Kelun-Biotech Announces Three Clinical Study Results Selected for Oral Presentations at 2026 ASCO Annual Meeting
projects are in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit
More news about: Kelun-Biotech
Apr 20, 2026, 22:54 ET Cadonilimab Combination Demonstrates Promising Survival Benefit in Locally Advanced Pancreatic Cancer: Phase II COMPASSION-26 Data Presented at AACR 2026
established a robust R&D innovation ecosystem centered on its Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.
More news about: Akeso, Inc.
Apr 20, 2026, 09:30 ET Hesai Unveils Picasso 6D Full-Color SPAD-SoC, Next-Gen ETX, and Innovations in Spatial Intelligence and Physical AI
lidar technologies. Following the launch of Fermi C500, a RISC-V-based high-performance lidar controller SoC that integrates MCU, FPGA functions, and ADC into a single chip, the company has established full-stack in-house ASIC development capabilities. This technology foundation has already
More news about: Hesai Technology
Apr 20, 2026, 08:00 ET Adcendo ApS Provides Updates on Pipeline Progress and Recent Achievements for Its First- and Best-in-Class Antibody-Drug Conjugates
a novel TF-targeting ADC with a potentially superior therapeutic window.ADCE-D01 granted Orphan Drug Designation by U.S. FDA. ADCE-D01 is a first-in-class ADC targeting uPARAP conjugated to the Topo- I inhibitor payload P1021. uPARAP is a novel endocytic receptor ADC target that is overexpressed
More news about: Adcendo
Apr 20, 2026, 08:00 ET Adcendo ApS Provides Updates on Pipeline Progress and Recent Achievements for Its First- and Best-in-Class Antibody-Drug Conjugates
a novel TF-targeting ADC with a potentially superior therapeutic window.ADCE-D01 granted Orphan Drug Designation by U.S. FDA. ADCE-D01 is a first-in-class ADC targeting uPARAP conjugated to the Topo- I inhibitor payload P1021. uPARAP is a novel endocytic receptor ADC target that is overexpressed
More news about: Adcendo
Apr 20, 2026, 06:45 ET U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
recurrence.viiiAbout PADCEV™ (enfortumab vedotin-ejfv) PADCEV™ (enfortumab vedotin-ejfv) is a first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4, a protein located on the surface of cells and highly expressed in bladder cancer.ix Nonclinical data suggest
More news about: Astellas Pharma Inc.
Apr 19, 2026, 20:15 ET CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3)
CS5007 (EGFR/HER3 ADC), CS5006 (ITGB4 ADC), and CS5008 (DLL3/SSTR2 ADC). CStone's Proprietary ADC Technology PlatformAll three antibody-drug conjugates (ADCs) presented at AACR – CS5007 (EGFR/HER3 ADC), CS5006 (ITGB4 ADC), and CS5008 (DLL3/SSTR2 ADC) – are developed
More news about: CStone Pharmaceuticals
Apr 19, 2026, 18:00 ET Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026
antibody drug conjugate (ADC) cancer treatments, today announced the presentation of new preclinical data across its ADC portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22, 2026, in San Diego, CA."Across our three ADC programs, we have a
More news about: Whitehawk Therapeutics, Inc.
Apr 17, 2026, 20:30 ET Antengene Presents Three Novel Programs at AACR 2026, Highlighting Next-Generation ADC and AnTenGager® TCEs
Cancer Research Annual Meeting (AACR 2026). The presentations will feature ATG-125 (B7-H3 x PD-L1 bispecific antibody-drug conjugate [ADC]), an IO + ADC dual-function molecule being developed for the treatment of solid tumors, as well as two investigational T cell engagers (TCEs) developed using
More news about: Antengene Corporation Limited
Apr 17, 2026, 08:30 ET Marengo Reports Late-Breaking Initial Phase 2 Clinical Results from Invikafusp Alfa Plus TRODELVY® and Unveils Partnered Novel IPN01203/STAR0501 STAR Program in Phase 1 at AACR 2026
IPN01203/STAR0501, being advanced in partnership with Ipsen in the prestigious New Drugs on the Horizon session."Combining invikafusp alfa with ADC-mediated immunogenic tumor killing is a scientifically compelling approach, and it is exciting to see this translate into meaningful clinical responses
More news about: Marengo Therapeutics
Apr 17, 2026, 04:19 ET Piramal Pharma Solutions e Ajinomoto Bio-Pharma Services collaborano per supportare lo sviluppo e la produzione di ADC
centinaia di ADC, realizzato migliaia di lotti e attualmente produce numerosi ADC a uso commerciale. Le attuali attività di ampliamento stanno incrementando la capacità produttiva di Piramal per gli ADC su scala commerciale.La tecnologia AJICAP™ di Ajinomoto supporta lo sviluppo di ADC e linker sito-specifici
More news about: Piramal Pharma Solutions
Apr 16, 2026, 16:05 ET Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series
clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced Dave Lennon, PhD, President and CEO, will participate in a virtual fireside chat as part of the Jones Trading Post-AACR
More news about: Whitehawk Therapeutics, Inc.
Apr 16, 2026, 13:12 ET Piramal Pharma Solutions und Ajinomoto Bio-Pharma Services arbeiten zusammen, um die Entwicklung und Herstellung von ADCs zu unterstützen
Geschwindigkeit herzustellen.Als weltweit erstes von der FDA zugelassenes ADC CDMO bringt Piramal mehr als zwei Jahrzehnte Erfahrung in diesem Bereich mit. Das Unternehmen leistete auch Pionierarbeit bei der kommerziellen ADC-Herstellung und verfügt damit über mehr als 15 Jahre Fachwissen. Piramal verfügt
More news about: Piramal Pharma Solutions
Apr 16, 2026, 08:30 ET Piramal Pharma Solutions y Ajinomoto Bio-Pharma Services colaboran en el desarrollo y fabricación de ADC
desarrollado cientos de ADC, completado miles de lotes y actualmente fabrica varios ADC comerciales. Las continuas expansiones están incrementando la capacidad de producción de ADC a escala comercial de Piramal.La tecnología AJICAP™ de Ajinomoto facilita el desarrollo de ADC y tecnologías de enlace
More news about: Piramal Pharma Solutions
Apr 16, 2026, 08:00 ET Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing
manufacture AJICAP™-based products with precision and speed.As the world's first FDA-approved ADC CDMO, Piramal brings over two decades of experience to the field. The Company also pioneered commercial ADC manufacturing, earning it more than 15 years of specialized expertise. With a global network of
More news about: Piramal Pharma Solutions
Apr 16, 2026, 08:00 ET Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing
manufacture AJICAP™-based products with precision and speed.As the world's first FDA-approved ADC CDMO, Piramal brings over two decades of experience to the field. The Company also pioneered commercial ADC manufacturing, earning it more than 15 years of specialized expertise. With a global network of
More news about: Piramal Pharma Solutions